SEC Form 4 · accession 0001562180-16-003658
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L Tubridy
Officer — SVP, Chief Development Officer
Period of report
Nov 30, 2016
Accepted (ET)
Dec 2, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1 | $8.61 | Nov 30, 2016 | A | 130,000 | A | — | Nov 30, 2026 | Common Stock | 130,000 | 130,000 | D |
Explanation of responses
- F1This option will vest as to 25% of the shares of common stock subject to the award on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.